Compare Recursion Pharmaceuticals Inc (RXRX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Waste Management, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B), while Waste Management, Inc. trades at $209.6 (market cap $83.98B). The key difference: Waste Management, Inc. is far larger — about 39.2× Recursion Pharmaceuticals Inc's market cap, and Waste Management, Inc. pays a 1.8% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Waste Management, Inc. for 130 Days on average.
| RXRX | WM | |
|---|---|---|
Market Cap | $2.14B | $83.98B |
Volume | 30,789,535 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $6.79 | $246.51 |
52-Week Low | $2.84 | $196.77 |
Typical Hold Time | 22 Days | 130 Days |
Enterprise Value | $1.66B | $106.78B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Waste Management (WM) trades at $208.94, up 0.51% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $25.2B revenue in 2025, 11.12% net margin, and consistent earnings beats in recent quarters. Recent news highlights WM's defensive business model and dividend reliability, while analyst consensus remains strongly positive with 57% buy ratings.
WM presents a compelling long-term investment with stable cash flows and dividend growth potential, though elevated debt levels and near-term technical weakness warrant caution. The stock's premium valuation (P/E 29.55) reflects quality but limits near-term upside absent significant earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
